+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are studying adolescents aged 12 to under 18 years with asthma who have had at least one severe asthma attack in the past year. This trial compares the effects of two inhalers a combination budesonidealbuterol inhaler and an albuterol-only inhaler, both used as needed. The goal is to see which inhaler better reduces severe asthma exacerbations over one year. Participants will be randomly assigned to use either the budesonidealbuterol inhaler or the albuterol inhaler as needed, in addition to their usual asthma maintenance therapy. The study lasts 52 weeks and includes a 7 to 28 day screening period before treatment and a safety follow-up period of 7 to 14 days after treatment ends. A separate pharmacokinetic sub-study involves a single visit after safety follow-up to evaluate drug levels after one dose of the budesonidealbuterol inhaler. During the study, participants will be regularly monitored for asthma attacks and medication use. Researchers will assess lung function, inhaler technique, and collect safety information including any adverse events. The main outcome is the annual rate of severe asthma exacerbations. Additional measures include time to first severe attack and corticosteroid use. Participants will complete peak flow measurements and have urine pregnancy tests if applicable. The total participation duration is approximately one year plus follow-up.

Age: 12Years - 17YearsAll GendersPhase 3
155 locations
S

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of PL-14 Allergy Blocker compared to saline spray in adults with Seasonal Allergic Rhinitis SAR, a common condition causing symptoms like sneezing, nasal congestion, and itching triggered by airborne allergens. PL-14 Allergy Blocker is a drug-free intranasal hydrogel designed to form a mechanical barrier on the nasal lining to reduce allergen contact. This prospective, randomized, single-blind study plans to enroll up to 120 participants at multiple sites in the United States. Participants with a history of seasonal allergic rhinitis will first undergo a treatment-free run-in period, then be randomly assigned to self-administer either PL-14 Allergy Blocker or Ayr4 Saline Nasal Mist for up to 30 days. The study focuses on comparing these two devices to assess their effects on nasal allergy symptoms, quality of life, use of rescue medications, and symptom-free days. The active treatment period primarily covers the first 14 days, with continued assessments throughout the 30-day administration. During the study, participants will complete symptom scoring questionnaires, quality of life assessments, and record medication use. Safety will be monitored through adverse event tracking, nasal examinations, and evaluations of local tolerability. Participants will attend multiple visits over approximately 37 days, including screening, treatment, and follow-up phases, allowing researchers to measure the daily reflective Total Nasal Symptom Score and overall impact on allergy symptoms and safety.

Age: 18Years - 75YearsAll GendersPhase Not Applicable
5 locations
L

Actively Recruiting

Researchers are evaluating the long-term reliability and performance of cardiac rhythm products marketed by Medtronic. This observational study focuses on devices such as leads, implantable pulse generators, implantable cardioverter defibrillators, and cardiac resynchronization therapy devices used for conditions like arrhythmia, bradycardia, heart failure, and sinus tachycardia. The study aims to analyze product survival probabilities and monitor lead-related complications over time. Participants include individuals who have received or will receive Medtronic market-released cardiac devices for pacing, sensing, or defibrillation. The study includes products implanted as part of routine care or participants from prior qualifying studies. Data is collected from the time of implantation and continues until the device is removed from service, the patient exits the study, or passes away. Enrollment criteria also require consent for access to health information. During the study, participants device performance is monitored through follow-up data collection. Researchers assess complications related to the implanted leads and track device status over long periods, potentially spanning several years. The study does not involve additional treatments but relies on routine clinical follow-up and health information review. The total duration extends up to December 2040, allowing comprehensive long-term evaluation of device performance.

All AgesAll Genders
338 locations